Codexis, Inc. (CDXS) |
| 2.24 -0.16 (-6.67%) 04-10 16:00 |
| Open: | 2.41 |
| High: | 2.46 |
| Low: | 2.165 |
| Volume: | 1,476,219 |
| Market Cap: | 204(M) |
| PE Ratio: | -4.48 |
| Exchange: | NASDAQ Global Select |
| Industry: | Biotechnology |
| Sector: | Healthcare |
| Technical analysis | ||||
![]() |
||||
| sell | buy | |||
| Resistance 2: | 2.87 |
| Resistance 1: | 2.46 |
| Pivot price: | 1.82 |
| Support 1: | 1.65 |
| Support 2: | 1.15 |
| 52w High: | 3.87 |
| 52w Low: | 0.96 |
Codexis, Inc. discovers, develops, and sells enzymes and other proteins. It offers biocatalyst products and services; intermediate chemicals products that are used for further chemical processing; and Codex biocatalyst panels and kits that enable customers to perform chemistry screening. The company also provides biocatalyst screening and protein engineering services. In addition, it offers CodeEvolver protein engineering technology platform, which helps in developing and delivering biocatalysts that perform chemical transformations and enhance the efficiency and productivity of manufacturing processes. The company's platform is also used to discover novel biotherapeutic drug candidates for targeted human diseases, as well as for molecular biology and in vitro diagnostic enzymes. It sells its products to pharmaceutical manufacturers through its direct sales and business development force in the United States and Europe. The company was incorporated in 2002 and is headquartered in Redwood City, California.
| EPS | -0.500 |
| Book Value | 0.560 |
| PEG Ratio | 0.00 |
| Gross Profit | 0.096 |
| Profit Margin (%) | -62.47 |
| Operating Margin (%) | 35.89 |
| Return on Assets (ttm) | -16.1 |
| Return on Equity (ttm) | -74.9 |
Sat, 11 Apr 2026
Analyst sentiment unchanged after Codexis (CDXS) earnings - MSN
Fri, 10 Apr 2026
Codexis, Inc. (CDXS) Stock Price Today & Analysis - Gotrade
Wed, 08 Apr 2026
Aberdeen Group plc Raises Stake in Codexis, Inc. $CDXS - MarketBeat
Thu, 26 Mar 2026
Vanguard disaggregates holdings; Codexis Inc (NASDAQ: CDXS) shows 0 shares - Stock Titan
Thu, 12 Mar 2026
Codexis Posts Strong Q4, Eyes siRNA Market With ECO Synthesis Platform (NASDAQ:CDXS) - Seeking Alpha
Thu, 12 Mar 2026
Codexis stock rises after Q4 beat, outlook (CDXS:NASDAQ) - Seeking Alpha
|
StockChart iOS |
StoxlineLite iOS |
StoxlineLite iOS |
OptionCalc iOS |
|
StockChart Android |
StoxlineLite Android |
StoxlinePro Android |
OptionCalc Android |